Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

News

$Arcutis Biotherapeutics (ARQT.US)$ Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
2
Translate
Report
4721 Views
Comment
Sign in to post a comment
3581Followers
23Following
53KVisitors
Follow